Darenzepine

CAS No. 84629-61-8

Darenzepine( —— )

Catalog No. M32876 CAS No. 84629-61-8

Darenzepine is a muscarinic receptor inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 472 In Stock
5MG 427 In Stock
10MG 599 In Stock
25MG 889 In Stock
50MG 1163 In Stock
100MG 1572 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Darenzepine
  • Note
    Research use only, not for human use.
  • Brief Description
    Darenzepine is a muscarinic receptor inhibitor.
  • Description
    Darenzepine is a muscarinic receptor inhibitor extracted from patent US 20170095465 A1.
  • In Vitro
    Darenzepine is a muscarinic receptor inhibitor which is useful for the treatment of CNS disorders.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    AChR
  • Recptor
    AChR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    84629-61-8
  • Formula Weight
    347.41
  • Molecular Formula
    C21H21N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(\C(=O)N1CCN(C)CC1)=C/2\C=3C(C(=O)NC=4C2=CC=CC4)=CC=CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Eric Elenko, et al. Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation. US 20170095465 A1.
molnova catalog
related products
  • Otenzepad

    Otenzepad is a selective antagonist of M2 mAChR with IC50s of 386 nM and 640 nM for rat heart and rabbit peripheral lung.

  • PHA 543613

    PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.

  • SCH-900271

    SCH-900271 is a potent nicotinic acid receptor for the treatment of dyslipidaemia and is commonly used in the study of mixed hyperlipidaemia and primary hypercholesterolaemia.